Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - SALIX PHARMACEUTICALS LTD | d613744dex991.htm |
| EX-99.2 - EX-99.2 - SALIX PHARMACEUTICALS LTD | d613744dex992.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 11, 2013
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 000-23265 | 94-3267443 | |
| (Commission File Number) | (IRS Employer ID Number) |
| 8510 Colonnade Center Drive, Raleigh, North Carolina | 27615 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code (919) 862-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On October 11, 2013, Salix Pharmaceuticals, Ltd. (the “Company”) issued a press release announcing that that presentations related to Company products are scheduled to take place during the American College of Gastroenterology 2013 Annual Scientific Meeting. A copy of this press release is attached as Exhibit 99.1.
On October 14, 2013 the Company issued a press release announcing the availability of Ulcerative Colitis For Dummies®, Special Edition. A copy of this press release is attached as Exhibit 99.2.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. |
Description | |
| 99.1 | Press release dated October 11, 2013. | |
| 99.2 | Press release dated October 14, 2013. | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| SALIX PHARMACEUTICALS, LTD. | ||
| Date: October 17, 2013 | ||
| /s/ Adam C. Derbyshire | ||
| Adam C. Derbyshire | ||
| Executive Vice President and Chief Financial Officer | ||